Quarterly report pursuant to Section 13 or 15(d)

Note Payable - Additional Information (Detail)

v3.3.1.900
Note Payable - Additional Information (Detail)
 3 Months Ended
Jun. 30, 2015
USD ($)
Installments
Feb. 29, 2016
USD ($)
Installments
$ / System_Unit
shares
Nov. 30, 2015
USD ($)
Debt Instrument [Line Items]      
Note payable   $ 790,957 $ 868,947
Number of Prepacyte CB Processing System Units to be sold | shares   4,000  
Per unit amount on completion of sales criteria | $ / System_Unit   25  
Notes payable, principal amount outstanding   $ 1,100,944 $ 1,176,367
Maximum [Member]      
Debt Instrument [Line Items]      
Number of Prepacyte CB Processing System Units to be sold | shares   8,000  
Minimum [Member]      
Debt Instrument [Line Items]      
Number of Prepacyte CB Processing System Units to be sold | shares   4,000  
Notes Payable [Member]      
Debt Instrument [Line Items]      
Monthly installment amount   $ 29,938  
Asset purchase agreement commencement date Jul. 31, 2015    
Asset purchase agreement closing date Jun. 30, 2019    
Notes payable, number of installments paid | Installments   3  
Notes payable, interest expense   $ 14,391  
Asset Purchase Agreement [Member]      
Debt Instrument [Line Items]      
Note payable $ 1,300,000    
Reduction in note payable   120,000  
Notes payable, principal amount outstanding   1,300,000  
Asset Purchase Agreement [Member] | Maximum [Member]      
Debt Instrument [Line Items]      
Reduction in note payable   $ 100,000  
Asset Purchase Agreement [Member] | Notes Payable [Member]      
Debt Instrument [Line Items]      
Number of monthly installments | Installments 48    
Repayment interval   Monthly  
Monthly installment amount $ 29,938    
Annual interest rate 5.00%